New hope for stubborn seizures? Real-World drug study launches
NCT ID NCT06716801
Summary
This study aims to see how well the drug cenobamate works for adults with focal epilepsy when added to their current medications in a real-world setting. It will observe 300 patients in France, Germany, and Spain whose seizures are not well controlled by 2-3 other anti-seizure drugs. The main goal is to see how many patients have their seizure frequency cut in half or more over 6 and 12 months, while also checking safety and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY WITH AND WITHOUT SECONDARY GENERALIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital TARNIER COCHIN
RECRUITINGParis, France, France
Contact
Conditions
Explore the condition pages connected to this study.